… in various patient populations, published PK data in obesity are limited to a … steady-state
pharmacokinetics of piperacillin and tazobactam administered by prolonged infusion in obese …

… /tazobactam in hospitalized obese and nonobese patients. Therefore, the … steady-state
population pharmacokinetics of piperacillin and tazobactam, administered by prolonged infusion, …

… the steady-state population pharmacokinetics of piperacillin and tazobactam when administered
by extended infusion in … Additionally, we evaluated the pharmacodynamics of TZP using …

… On Day 2 (fifth piperacillin/tazobactam bolus dose or change … that continuous infusion of
piperacillin maintains superior … in critically ill patients with sepsis at first dose and at steady state. …

… patient population, the purpose of this study was to evaluate the steady-state
pharmacokinetic-pharmacodynamic … regimens were apparently negated, and the use of extended …

… Steady-state pharmacokinetic data were obtained from 13 patients who received
piperacillin/tazobactam 4.5 g every 8 hours, infused over 4 hours. Monte Carlo simulations (10,000 …

… 6 h in hemodialysis patients to a 27 g/24-h continuous infusion in a patient with a short PT
half-… Predicted free steady-state piperacillin troughs on 4.5 g every 6 h are displayed in Fig. 1, …

… a reduced average serum steady-state concentration: 39.8 mg/… dosing schemes with
piperacillin/tazobactam. Future studies … or continuous infusion dosing schemes for obese …

… A free fraction of 70% was used, as piperacillin/tazobactam is known to be approximately
30… patient, were compared with the parameters determined at the same dose at steady state in …

… Simulated steady-state concentrations were 1.43-times, 95%CI = (1.27; 1.61), higher in …
We could further show that prolonged and continuous infusions might be necessary for MIC …